If approved, CUTX-101 will be the first and only FDA-approved treatment available for Menkes disease, a rare X-linked recessive pediatric genetic disease that impacts an estimated 1 in 34,810 to as high as 1 in 8,664 live male births. Shares of Zydus Lifesciences Ltd ended at ₹923, down by ₹6.15, or 0.66%, on the BSE today, December 15.
